Formosa Pharma ships APP13007 ophthalmic drug to US

APP13007 is the first US FDA-approved ophthalmic solution featuring the super-potent corticosteroid clobetasol propionate.

Vishnu Priyan September 09 2024

Formosa Pharmaceuticals has announced the first shipment of its ophthalmic asset, clobetasol propionate ophthalmic suspension 0.05% (APP13007),to the US to facilitate commercialisation.

The drug, developed using Formosa's APNT nanotechnology platform, is the first US Food and Drug Administration (FDA)-approved ophthalmic solution featuring the super-potent corticosteroid clobetasol propionate.

Bora Pharmaceuticals Ophthalmic has manufactured the shipment of APP13007, which offers a twice-daily dosing regimen that is more convenient than the four doses per day required by other treatments.

Eyenovia, Formosa Pharma's US partner, initiated pre-launch activities and is expected to begin the commercialisation of APP13007 by late September 2024.

In 2023, Eyenovia acquired exclusive licensing and commercialisation rights for APP13007 in the US from Formosa Pharmaceuticals in an $86m deal.

In August 2024, Formosa obtained a drug export licence from Taiwan's Food and Drug Administration.

The licence has enabled the company to co-ordinate its first shipment to the US, a key step in its strategy for global commercialisation.

In anticipation of demand within the US market, Formosa is also collaborating with partners in other regions to prepare for regulatory submissions.

The goal is to make APP13007 available in international markets, expanding its reach beyond the US.

Formosa Pharmaceuticals focuses primarily on ophthalmology and oncology.  

Its APNT technology enhances the dissolution, bioavailability and stability of active pharmaceutical ingredients, enabling the use of poorly soluble or highly potent drug agents.

Formosa Pharma president and CEO Dr Erick Co said, “This first shipment to Eyenovia for the much-anticipated commercial US launch is an exclamation point on our development of APP13007. 

“We thank all our partners for making this journey with us and are eager to provide this formidable therapy to ocular surgery patients worldwide.  We look forward to creating continued value for our stakeholders and shareholders.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close